פגסיס 135 מק"ג/0.5 מ"ל

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

PEGINTERFERON ALFA 2A 135 MCG / 0.5 ML

Disponible depuis:

ROCHE PHARMACEUTICALS (ISRAEL) LTD

Code ATC:

L03AB11

forme pharmaceutique:

SOLUTION FOR INJECTION

Mode d'administration:

S.C

Fabriqué par:

HOFFMANN LA ROCHE LTD, SWITZERLAND

Groupe thérapeutique:

PEGINTERFERON ALFA-2A

indications thérapeutiques:

Chronic Hepatitis B: Pegasys is indicated for the treatment of both HBeAg- positive and HBeAg -negative chronic hepatitis B in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.Chronic Hepatitis C: Pegasys is indicated for the treatment of chronic hepatitis C in adult patients who are positive for serum HCV-RNA including patients with compensated cirrhosis and/or co-infected with clinically stable HIV. The optimal way to use Pegasys in patients with chronic hepatitis C is in combination with ribavirin. The combination of Pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

Date de l'autorisation:

2013-09-01